BridgeBio Director Gets $625K Stock Package in Latest Board Compensation

[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma Director Hannah Valantine reported multiple equity transactions on June 20, 2025:

Received 6,589 Restricted Stock Units (RSUs) at $0 cost, vesting over three years through June 20, 2028
Granted 8,425 stock options with strike price of $41.73, exercisable until June 19, 2035
Options and RSUs vest in three equal annual installments starting June 20, 2025

Following these transactions, Valantine's holdings include:

Direct ownership: 8,353 common shares and 8,425 stock options
Indirect ownership: 3,433 shares held by spouse

These grants appear to be part of standard director compensation under the company's 2021 Amended and Restated Stock Option and Incentive Plan. All vesting is contingent on continued board service.

06/24/2025 - 06:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valantine Hannah

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/20/2025		A⁽¹⁾		6,589	A	$0⁽²⁾	8,353	D
Common Stock								3,433	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$41.73	06/20/2025		A		8,425		⁽³⁾	06/19/2035	Common Stock	8,425	$0	8,425	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

	/s/ Hannah A. Valantine, M.D.	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many BBIO shares did Hannah Valantine receive in RSUs on June 20, 2025?

Hannah Valantine received 6,589 restricted stock units (RSUs) of BBIO common stock on June 20, 2025. These RSUs will vest over three years, with one-third vesting each year from June 20, 2025 to June 20, 2028, subject to her continued service on the board of directors.

What stock options did BBIO's director Hannah Valantine receive in June 2025?

On June 20, 2025, Hannah Valantine received stock options to purchase 8,425 shares of BBIO common stock at an exercise price of $41.73 per share. The options expire on June 19, 2035 and vest over three years, with one-third vesting each year through June 20, 2028.

How many BBIO shares does Hannah Valantine own directly and indirectly?

Following the reported transactions, Hannah Valantine directly owns 8,353 shares of BBIO common stock and indirectly owns 3,433 shares through her spouse. She also holds 8,425 unvested stock options and 6,589 unvested RSUs.

What is the vesting schedule for BBIO director Hannah Valantine's June 2025 equity grants?

Both the RSUs and stock options granted on June 20, 2025 follow the same vesting schedule: one-third will vest each year over three years, with full vesting achieved on June 20, 2028, contingent upon Valantine's continued service on BBIO's board of directors.

AG真人官方

[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

FAQ

How many BBIO shares did Hannah Valantine receive in RSUs on June 20, 2025?

What stock options did BBIO's director Hannah Valantine receive in June 2025?

How many BBIO shares does Hannah Valantine own directly and indirectly?

What is the vesting schedule for BBIO director Hannah Valantine's June 2025 equity grants?

NASDAQ:BBIO

BBIO Rankings

BBIO Latest News

BBIO Latest SEC Filings

BBIO Stock Data

AG真人官方

Trending News

[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

FAQ

How many BBIO shares did Hannah Valantine receive in RSUs on June 20, 2025?

What stock options did BBIO's director Hannah Valantine receive in June 2025?

How many BBIO shares does Hannah Valantine own directly and indirectly?

What is the vesting schedule for BBIO director Hannah Valantine's June 2025 equity grants?

NASDAQ:BBIO

BBIO Rankings

BBIO Latest News

BBIO Latest SEC Filings

BBIO Stock Data